Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uveal Melanoma 2 Lymphoma, T-Cell, Cutaneous 2 Lichen Planus, Oral 2 Stomach Neoplasms 1 Retinal Diseases 1 Recurrence 1 Radiodermatitis 1 Pancreatitis, Chronic 1 Pancreatic Neoplasms 1 Pain 1 Neuroma, Acoustic 1 Mycosis Fungoides 1 Melanoma 1 Macular Degeneration 1 Lymphomatoid Papulosis 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Leiomyoma 1 Glioblastoma 1 Fibroma 1 Exanthema 1 Esophageal Stenosis Acquired 1 Dupuytren Contracture 1 Disease 1 Dermatitis, Contact 1 Choroid Diseases 1 Chalazion 1 Castration Resistant Prostate Cancer 1

Interventions

Carboplatin 177 Radiotherapy 139 Cisplatin 110 Pemetrexed 102 Docetaxel 93 Paclitaxel 92 Gemcitabine 78 Erlotinib Hydrochloride 73 Magnetic Resonance Spectroscopy 72 Radiosurgery 67 Bevacizumab 65 pembrolizumab 64 Etoposide 60 Blood Specimen Collection 60 durvalumab 53 Specimen Handling 48 Nivolumab 48 Surveys and Questionnaires 47 Drug Therapy 41 Standard of Care 35 Radiation 33 osimertinib 32 atezolizumab 32 Surgical Procedures, Operative 30 Topotecan 29 Irinotecan 29 Gefitinib 29 Educational Status 29 Early Intervention, Educational 29 Biopsy 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lung Neoplasms × Triamcinolone Acetonide × Clear all

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡